When treated with Tubastatin A (TubA), ACY-775, or siRNA against HDAC6, a significant reduction in the proliferation, migration, and resistance to apoptosis of PAH-PASMCs was observed [63]. Here, HDAC6 is linked to pulmonary arterial hypertension.